Dynamic Medicine — Part IV : Why Drug Development Fails: A Systems Perspective on Therapeutic Breakdown

Description This paper is part of the Dynamic Medicine conceptual series, which reframes disease and treatment through a systems-dynamic perspective grounded in the Universal Resonance Model (URM). Dynamic Medicine — Part IV examines why modern drug development continues to fail at high rates despite advances in molecular biology, computational modeling, and clinical trial infrastructure. Rather than attributing failure to biological complexity or insufficient targets, the paper argues that many therapies are evaluated outside their effective dynamic window—without regard to disease phase, system stability, or adaptive capacity. By analyzing drug development through the lens of system dynamics, timing, and phase mismatch, this work explains why late-stage trials disproportionately fail, why patient variability is misinterpreted as noise, and why potentially effective therapies are abandoned prematurely. This is a conceptual paper. It introduces no new clinical data and does not review existing literature. Its purpose is to clarify structural limitations in current development paradigms and to provide a theoretical foundation for phase-aware, timing-sensitive therapeutic design in future work.